iRhythm Technologies (IRTC) – Investment Analysts’ Recent Ratings Changes

iRhythm Technologies (NASDAQ: IRTC) recently received a number of ratings updates from brokerages and research firms:

• 8/10/2026 – iRhythm Technologies had its price target raised by Truist Financial Corporation from $160.00 to $168.00. They now have a “buy” rating on the stock.
• 8/8/2026 – iRhythm Technologies was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/7/2026 – iRhythm Technologies had its price target lowered by Needham & Company LLC from $255.00 to $192.00. They now have a “buy” rating on the stock.
• 8/7/2026 – iRhythm Technologies had its price target lowered by Wells Fargo & Company from $180.00 to $168.00. They now have an “overweight” rating on the stock.
• 7/23/2026 – iRhythm Technologies is now covered by Stephens. They set an “overweight” rating and a $160.00 price target on the stock.
• 7/22/2026 – iRhythm Technologies was upgraded by Stephens to “strong-buy”.
• 7/18/2026 – iRhythm Technologies was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/16/2026 – iRhythm Technologies had its price target lowered by Truist Financial Corporation from $174.00 to $160.00. They now have a “buy” rating on the stock.
• 6/22/2026 – iRhythm Technologies had its “buy” rating reaffirmed by BTIG Research. They now have a $185.00 price target on the stock.
• 6/18/2026 – iRhythm Technologies was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.